Oric Pharmaceuticals Files 8-K

Ticker: ORIC · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1796280

Oric Pharmaceuticals, Inc. 8-K Filing Summary
FieldDetail
CompanyOric Pharmaceuticals, Inc. (ORIC)
Form Type8-K
Filed DateJan 13, 2025
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, disclosure, financials

TL;DR

ORIC filed a routine 8-K on Jan 13, 2025. No major news.

AI Summary

Oric Pharmaceuticals, Inc. filed an 8-K on January 13, 2025, to report information under Regulation FD and to file financial statements and exhibits. The filing does not contain specific financial details or material events beyond the standard reporting requirements for this form.

Why It Matters

This 8-K filing serves as a routine disclosure for Oric Pharmaceuticals, Inc., providing updates on regulatory matters and financial statements without announcing new material events.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for Regulation FD disclosure and financial statements, indicating no new material events or risks.

Key Players & Entities

  • Oric Pharmaceuticals, Inc. (company) — Registrant
  • January 13, 2025 (date) — Date of Report
  • 240 E. Grand Ave, 2nd Floor South San Francisco, CA 94080 (address) — Principal executive offices

FAQ

What is the primary purpose of this 8-K filing by Oric Pharmaceuticals, Inc.?

The primary purpose of this 8-K filing is to report information under Regulation FD Disclosure and to file Financial Statements and Exhibits.

On what date was this 8-K report filed?

This 8-K report was filed on January 13, 2025.

What is the principal executive office address for Oric Pharmaceuticals, Inc.?

The address of the principal executive offices is 240 E. Grand Ave, 2nd Floor, South San Francisco, CA 94080.

What is the Standard Industrial Classification (SIC) code for Oric Pharmaceuticals, Inc.?

The Standard Industrial Classification code for Oric Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Does this 8-K filing announce any new material events or agreements?

Based on the provided text, this 8-K filing is for Regulation FD Disclosure and Financial Statements and Exhibits, and does not explicitly announce any new material events or agreements.

Filing Stats: 512 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2025-01-13 08:30:21

Key Financial Figures

  • $0.0001 — ich registered Common stock, par value $0.0001 per share ORIC The Nasdaq Global Se

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Corporate Presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ORIC PHARMACEUTICALS, INC. Date: January 13, 2025 By: /s/ Christian Kuhlen Christian Kuhlen, M.D., J.D. General Counsel

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.